Skip to main content

Table 4 Treatment Outcome of individual patients

From: Radiofrequency ablation for liver metastases in patients with gastric cancer as an alternative to hepatic resection

Clinical data

Liver metastasis

RFA

Recur

Case

Comorbidity

PS

No

Lobar

Chronicity

Size (cm)

CTx after RFA

Number of initial RFA

Recur

Pattern

Tx after recur

OS (mon)

DFS (mon)

Survivala

1

No

0

1

Uni

Meta

2.6

Yes

2

Yes

Liver

RFA

69.1

10.3

Death

2

Yes

1

1

Uni

Meta

3.7

Yes

1

Yes

Liver

CTx

20.7

0.8

Death

3

No

0

5

Bi

Meta

1

No

2

Yes

Liver

None

40.5

11.4

Death

4

No

1

2

Uni

Syn

2

Yes

1

No

  

79.6

42.3

Alive

5

Yes

1

1

Uni

Meta

1.7

No

1

Yes

Liver

RFA

21.8

4.7

Death

6

No

0

1

Uni

Meta

3.3

Yes

1

No

  

22.9

22.6

Alive

7

Yes

1

1

Uni

Meta

0.5

No

1

Yes

Virchow Node

CTx

12.8

9.4

Alive

8

Yes

0

1

Uni

Meta

1.5

No

1

Yes

Lung

None

25.1

8.9

Alive

9

Yes

2

1

Uni

Meta

4.2

No

1

Yes

Liver

None

20.0

7.9

Alive

10

Yes

1

1

Uni

Meta

3.7

No

1

No

  

3.6

3.3

Alive

11

No

2

2

Uni

Meta

3.2

NO

1

No

  

15.3

14.4

Alive

  1. PS, Performance status based on Eastern Cooperative Oncology Group, No number of metastatic lesion; Lobar, lobar distributaion; Uni, unilobar; Bi, bilobar; Meta, metachronous; Syn synchronous, CTx chemotherapy, Recur recurrence, Tx treatment, OS overall survival, DFS disease free survival, mon months
  2. aSurvival at the time of analysis